Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic
targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and …

Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as
prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In …

Four new series 7a-e, 8a-e, 9a-e, and 10a-e of 7-aryl-3-substituted pyrazolo [1, 5-a]
pyrimidines were synthesized and tested for their RTK and STK inhibitory activity …

The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-
cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor …

The treatment landscape of solid tumors has changed markedly in the last years.
Molecularly targeted treatments and immunotherapies have been implemented and have, in …

Despite consistent progress in prompt diagnosis and curative therapies in the last decade,
lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties …

Pulmonary adenocarcinomas (pADCs) with an ALK rearrangement are a rare cancer
subtype, necessitating comprehensive molecular investigations to unravel their …

The third-generation anaplastic lymphoma tyrosine kinase inhibitor (ALK-TKI) lorlatinib has
a unique side effect profile that includes hypercholesteremia and hypertriglyceridemia in> …

Introduction Several anaplastic lymphoma kinase (ALK)-inhibitors (ALKi) have been
approved for the treatment of ALK-translocated advanced or metastatic Non Small Cell Lung …

Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades,
the management of non-small cell lung cancer (NSCLC) has undergone a significant …